New York, USA – December 28, 2020 – Since the outbreak of COVID-19 last year, people from global countries are facing this threat which has already caused 1.66 million deaths worldwide by December 18, 2020. This has driven the undeniable conclusion that the research and development of effective COVID-19 antiviral drugs are highly urgent.
The inhibition of viral targets might be a method for COVID-19 treatment. The rational drug design identified as much of the recent discoveries of potent drugs molecule against any targets, which leads to an improvement in bindings for better potency and selectivity. With years of exploration in coronavirus including MERS-CoV, SARS-CoV, and SARS-CoV-2, Creative Biolabs has optimized the one-stop inhibitor development services, covering nucleoside analogue inhibitors, viral protease inhibitors, inhibitors of host cell protease, Abelson kinase inhibitors, RNA synthesis inhibitors, neuraminidase inhibitors, and antisense oligonucleotides.
The key enzymes involved in coronavirus RNA synthesis are the RdRp (nsp12), the helicase (nsp13), and the nsp7-nsp8 complex. Given their crucial function in the viral replicative cycle, they are key targets for antiviral research. Creative Biolabs now provides different kinds of strategies to develop anti-SARS-CoV-2 drugs, such as nucleoside analogues, guanosine analogue, adenosine analogue and siRNA for the treatment of SARS-CoV-2.
• Protease Inhibitors for SARS-CoV-2
Based on thousands of clinical drug libraries, scientists have already identified three small-molecule drugs with high binding potential to the coronavirus main protease through high-throughput screening, which can be used as candidate drugs for the treatment of SARS-CoV-2 infection. Creative Biolabs has optimized one-stop protease inhibitors development services, including Nelfinavir, Saquinavir, and Indinavir for SARS-CoV-2.
In addition to the comprehensive array of antiviral drug discovery services, Creative Biolabs also offers vaccine discovery services, including but not limited to live attenuated and killed vaccine development services for SARS-CoV-2, mRNA vaccine development services for SARS-CoV-2, SARS-CoV-2 DNA vaccine, and recombinant subunit vaccine development services for SARS-CoV-2.
“Since the epidemic broke out in 2019, we have quickly set up a professional team to carry out intensive analysis and research on SARS-CoV-2. Now we can provide both services and related proteins, antibodies, and other products to help global researchers quickly develop effective drugs and vaccines,” as introduced by a senior scientist at Creative Biolabs.
More information can be found on https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.